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Abstract
Background: Duhuo Jisheng Wan (DJW) is perhaps the best known and most widely used Chinese herbal
recipe for arthralgia, but the clinical study to verify its efficacy is lacking. The purpose of this study was to
compare the efficacy of DJW versus diclofenac in symptomatic treatment of osteoarthritis (OA) of the
knee.
Methods: This study was a randomized, double-blind, double-dummy, controlled trial. The 200 patients
suffering from OA of the knee, were randomized into the DJW and diclofenac group. The patients were
evaluated after a run-in period of one week (week 0) and then weekly during 4 weeks of treatment. The
clinical assessments included visual analog scale (VAS) score that assessed pain and stiffness, Lequesne's
functional index, time for climbing up 10 steps, as well as physician's and patients' overall opinions on
improvement.
Results: Ninety four patients in each group completed the study. In the first few weeks of treatment, the
mean changes in some variables (VAS, which assessed walking pain, standing pain and stiffness, as well as
Lequesne's functional index) of the DJW group were significantly lower than those of the diclofenac group.
Afterwards, these mean changes became no different throughout the study. Most of the physician's and
patients' overall opinions on improvement at each time point did not significantly differ between the two
groups. Approximately 30% of patients in both groups experienced mild adverse events.
Conclusion: DJW demonstrates clinically comparable efficacy to diclofenac after 4 weeks of treatment.
However, the slow onset of action as well as approximately equal rate of adverse events to diclofenac
might limit its alternative role in treatment of OA of the knee.
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Background
Osteoarthritis (OA) is the most prevalent joint disorder
characterized by articular cartilage degradation with an
accompanying peri-articular bone response [1]. OA affects
many joints, with diverse clinical patterns, but OA of the
hip and knee is the major cause of disability [2]. A clinical
manifestation of OA of the knee is pain in and around the
joint that is typically worse with weight-bearing and at
night. Other manifestations include morning stiffness,
stiffness after rest, crepitation on motion, limited joint
motion and/or joint deformity [3]. Although there are
many treatment modalities, OA is still widely treated with
nonsteroidal anti-inflammatory drugs (NSAIDs) [4].
Nonetheless, since the inflammatory component of OA is
usually minimal, a need for the anti-inflammatory effect
of NSAIDs used in this condition is still controversial [5-
7]. Moreover, long-term use of NSAIDs is also directly
related to many side effects, including gastrointestinal
bleeding, hypertension, congestive heart failure, hyperka-
lemia, and renal insufficiency [8]. Although some of these
disadvantages can be avoided by using paracetamol or
selective cyclooxygenase II (COX-II) inhibitors, long-term
use of paracetamol possibly leads to hepatotoxicity and
chronic renal impairment [9,10]. In addition, the rela-
tively high cost of selective COX-II inhibitors seems to be
unsuitable for Thailand's present socio-economic status.
The use of Chinese and other foreign patent herbal medi-
cines (pills and tablets) in arthralgia treatment is highly
prevalent and increasing in Thailand, but importing these
medicines from the People's Republic of China and other
foreign countries is usually rather expensive. However, the
cost of similar preparations can be minimized by using
imported dried herbs available in Thailand as raw materi-
als in the manufacturing process coupled with simple and
inexpensive traditional drug manufacturing techniques.
Thus, if clinical studies suggest that these herbal medi-
cines are as effective and/or less toxic than conventional
treatment, promotion of self-produced recipes in each
community will lead to community-directed osteoar-
thritic treatment in Thailand.
The herbal recipe used in this study was "Duhuo Jisheng
Wan (DJW)", which means pill of Pubescent angelica root
and Mulberry mistletoe combination, and it was quoted
from the book Bei Ji Qian Jing Yao Fang compiled by Sun
Simiao in the Tang Dynasty (652 A.D.) [11,12]. Although
this recipe is perhaps the best known and most widely
used formula for arthralgia and also sold as a patent rem-
edy [13], the clinical study to verify its efficacy (compared
with conventional treatment) is lacking. Thus, the objec-
tives of this study were to verify the efficacy of DJW and
compare its efficacy versus diclofenac in symptomatic
treatment of OA of the knee.
Methods
Research design
This randomized, double-blind, double-dummy, control-
led trial was approved by the Medical Ethics Committee of
the Faculty of Medicine, Chiang Mai University and was in
compliance with the Helsinki Declaration.
Subjects
Two hundred out-patients of either sex were recruited.
They were aged over 40 years, and had been suffering from
unilateral or bilateral OA of the knee according to the cri-
teria of the American College of Rheumatology [3] for
more than 3 months. After the use of usual medications
had ceased for 7 days, the visual analog scale (VAS) score
that assessed pain during the most painful knee move-
ment had to be more than 40, and Lequesne's functional
index [14] had to be over 7 points. Participants had to be
able to walk and give both verbal and written information
regarding the study. Signed informed consent was
obtained prior to entry. Exclusion criteria included an
underlying inflammatory arthropathy, hyperuricemia,
expectation of surgery in the near future, recent injury in
the area affected by OA of the knee, intra-articular corti-
costeroid injections within the last 3 months, hypersensi-
tivity to NSAIDs, abnormal liver or kidney function tests,
major abnormal finding on complete blood count, his-
tory of coagulopathies, history of peptic ulceration and
upper GI hemorrhage, uncontrolled hypertension, con-
gestive heart failure, hyperkalemia, pregnancy, lactation
and malignant tumors.
Treatment procedures
During a run-in period of 1 week (week 0), patients con-
sidered eligible for the study were informed to discon-
tinue all analgesics, anti-inflammatory drugs, and other
modalities for the treatment of arthralgia and arthritis. At
the beginning of week 1, patients who still met the eligible
criteria were randomized into 2 groups (DJW and
diclofenac group) and treated for 4 weeks (Table 1). Other
medications and treatment modalities for OA were pro-
hibited during the study. In addition, a count of unused
drugs and placebos was made weekly in order to check for
the rates of compliance with medication.
Table 1: Treatment in the DJW and diclofenac group.
Treatment DJW group Diclofenac group
Capsule Placebo Diclofenac
Herbal capsule DJW PlaceboBMC Complementary and Alternative Medicine 2004, 4:19 http://www.biomedcentral.com/1472-6882/4/19
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1. Diclofenac and its placebo
Twenty five mg film-coated tablets of commercially mar-
keted diclofenac sodium (Voltaren®) were provided by
Novartis (Thailand) Co., Ltd. In order to completely blind
the patients, each diclofenac tablet was packed into a cap-
sule with an appearance identical to its placebo. Either
diclofenac or placebo was prescribed at 1 capsule, 3 times
a day, immediately after meals.
2. DJW and its placebo
DJW and its placebo were prepared by the Department of
Pharmaceutical Sciences, Faculty of Pharmacy, Chiang
Mai University. It consisted of 7.75% each of Radix Angel-
icae Pubescentis (Duhuo), Radix Gentianae Macrophyllae
(Qinjiao), Cortex Eucommiae (Duzhong), Radix Achy-
ranthis Bidentatae (Niuxi), Radix Angelicae Sinensis
(Danggui), Herba Taxilli (Sangjisheng), Radix Rehman-
niae Preparata (Shudihuang), Rhizoma Chuanxiong
(Chuanxiong), Cortex Cinnamomi (Rougui) and Radix
Ledebouriellae (Fangfeng), 5% each of Radix Paeoniae
Alba (Baishao), Radix Codonopsis (Dangshen), Radix
Glycyrrhizae (Gancao) and Poria (Fuling), as well as 2.5%
of Herba Asari (Xixin).
Xixin, Niuxi, Shudihuang and Rougui were imported from
the Shantou Traditional Chinese Medicine Factory, the
People's Republic of China (PRC). The remaining herbs
were imported from the Qixin Co., Ltd. (Hebei Province),
PRC. Each pulverized ingredient was mixed thoroughly
together according to the formula mentioned above and
prepared into honeyed pills, which were baked in a hot air
oven until completely dry, and then pulverized. The pul-
verized powder was finally filled into capsules of 500 mg
per capsule. The quality control and standardization of
DJW (i.e., assessment of weight variation, disintegration
time, screening for microorganisms and aflatoxin) were
conducted by using guidelines recommended by the Food
and Drug Administration of Thailand [15]. DJW and its
placebo were prepared in 4 separate lots. Every lot had to
pass for quality control and standardization before pre-
scription and they were used within 8 weeks in order to
ascertain the stability of active substances, and avoid
microorganism and aflatoxin contamination during the
study. DJW was prescribed at 6 capsules (3 g) each time, 3
times a day, immediately after meals. Its placebo, with
identical appearance, was made from cane sugar and pre-
scribed at the same dosage as the DJW.
Assessments
Clinical assessments were evaluated for base-line data at
the end of a run-in period (week 0) and then weekly for 4
weeks. These assessments included 100-mm VAS that
assessed pain (classified into walking pain, standing pain,
pain during climbing up and down stairs, night pain, rest-
ing pain, total pain, pain during the most painful knee
movement), 100-mm VAS that assessed stiffness (classi-
fied into morning stiffness, stiffness after rest and total
stiffness), Lequesne's functional index that assessed the
patient's daily activities (score ranging from 0–24) [14],
and time for climbing up 10 steps. The participants self-
rated the VAS and Lequesne's functional index, and they
were allowed to view their own previously recorded
scores.
At the end of week 1–4, 100-mm VAS that assessed the
physician's and patients' overall opinions on improve-
ment were also evaluated. The assessment forms were
designed so that the patients and evaluator could view
their own previously recorded scores, but they were not
allowed to view each other's VAS. Clinical assessments
were evaluated by the same physician who had been
blinded to the treatment. Complete physical examination
and non-directive questioning for adverse events were
also performed weekly for 4 weeks in order to acquire a
safety assessment.
Statistical analysis
In within the group analysis, the mean VAS and
Lequesne's functional index between base-line and the
following weeks were compared by a non-parametric Wil-
coxon's signed-rank test, whereas, the average time for
climbing up 10 steps was compared by the paired t-test.
Flow chart of patients who participated in the clinical trial Figure 1
Flow chart of patients who participated in the clinical trial. 
1DJW group received DJW plus placebo of diclofenac. 
2Diclofenac group received diclofenac plus placebo of DJW.
Recruitment
(n = 429) 
Excluded during screening 
period (n = 229) 
Randomization
(n = 200) 
DJW group
1
(n = 100) 
Diclofenac group
2
(n = 100) 
Withdrawn (n = 4) 
Lost to follow up (n = 1)
Accident (n = 1) 
Completers
(n = 94)
Lost to follow up (n = 3) 
Accident (n = 3) 
Completers
(n = 94) BMC Complementary and Alternative Medicine 2004, 4:19 http://www.biomedcentral.com/1472-6882/4/19
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Table 2: Demographic data and base-line data for the major outcome assessments of participants evaluated at the end of a run-in 
period (week 0).
Treatment groups
Characteristics DJW Diclofenac p value
n (M:F) 100 (22:78) 100 (19:81) NS
Age (y)* 62.66 (9.46) 62.38 (8.22) NS
Body weight (kg)* 60.47 (10.34) 60.13 (10.89) NS
Height (m)* 1.51 (0.07) 1.51 (0.07) NS
BMI (kg/m2)* 26.52 (4.38) 26.35 (3.85) NS
Duration of OA (y)* 5.46 (5.48) 4.79 (4.24) NS
Localization of OA NS
Right knee 17 17
Left knee 14 14
Both knees 69 69
VAS the assessed pain (mm)*
Walking pain 64.53 (24.92) 64.78 (25.14) NS
Standing pain 52.42 (25.87) 53.52 (24.69) NS
Pain during climbing up and 
down stairs
63.08 (20.87) 62.69 (23.21) NS
Night pain 50.15 (26.74) 48.45 (28.18) NS
Resting pain 38.48 (22.09) 37.12 (26.08) NS
Total paina 268.65 (88.87) 266.55 (89.33) NS
Pain during the most painful 
knee movement
82.25 (16.15) 81.17 (16.56) NS
VAS that assessed stiffness (mm)*
Morning stiffness 53.53 (27.38) 58.32 (26.40) NS
Stiffness after rest 68.52 (22.76) 70.45 (22.32) NS
Total stiffnessb 122.05 (41.98) 128.76 (42.34) NS
Lequesne's functional index* 14.20 (3.13) 14.80 (2.61) NS
Time for climbing up 10 steps* 13.44 (4.85) 13.32 (5.10) NS
*Data represent mean (SD). aSummation of VAS that assessed walking pain, standing pain, pain during climbing up and down stairs, night pain and 
resting pain. bSummation of VAS that assessed morning stiffness and stiffness after rest. NS: no statistical significance.
Table 3: The radiographic findings at entry into the study.
Treatment groups
Radiographic findings DJW (169 knees) Diclofenac (169 knees) p value
Kellgren and Lawrence X-ray 
grade [20]
NS
Grade 2 31 23
Grade 3 71 80
Grade 4 67 66
Knee compartment with most 
severe changes
NS
Medial tibiofemoral 131 135
Lateral tibiofemoral 16 8
Patellofemoral 22 26BMC Complementary and Alternative Medicine 2004, 4:19 http://www.biomedcentral.com/1472-6882/4/19
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In the analysis between the groups, a non-parametric Wil-
coxon's rank-sum test was used to determine whether the
two groups differed in the physician's and patients' overall
opinions on improvement. In addition, the mean changes
in VAS that assessed pain and stiffness, as well as
Lequesne's functional index were compared by the same
test. The student's t-test was used to compare the mean
changes in the time for climbing up 10 steps.
Results
A total of 429 patients were recruited into this study, of
whom 229 were excluded (Figure 1). The remaining 200
patients were randomized into the DJW and diclofenac
group, 100 patients per group. In the DJW group, 4
patients withdrew from the study due to ineffectiveness (n
= 3) and transportation problem (n = 1), 1 patient was
lost to follow up and another one had a traffic accident
during the study. In the diclofenac group, 3 patients were
lost to follow up and 3 were withdrawn due to accidents.
Thus, each group comprised 94 completers. The two treat-
ment groups were not significantly different in demo-
graphic data e.g., sex, age, weight, height, duration of OA,
location of OA (Table 2) and base-line data for the major
outcome assessment (VAS, Lequesne's functional index
and time for climbing up 10 steps). The radiographic find-
ings at entry (Table 3) were not different between both
groups. During the study, the rates of compliance with
medication in the DJW group were 94%, whereas, those in
the diclofenac group were 96%. Since few patients with-
drew from the trial, the results were not substantially
affected, whether the statistical method was performed by
an intention to treat (ITT) analysis or an analysis on avail-
able completers. Thus, the following data showed the
findings from the ITT analysis.
The VAS that assessed pain and stiffness at the end of week
1–4 decreased significantly when compared to their own
base-line values (within the group analysis), as did
Lequesne's functional index and time for climbing up 10
steps (Table 4). At the end of week 4, the percentages of
improvement in VAS that assessed pain and stiffness were
higher than 65% in both groups, whereas, the percentages
of improvement in Lequesne's functional index and time
for climbing up 10 steps were approximately 40% and
20%, respectively.
Table 4: Mean VAS that assessed pain and stiffness, Lequesne's functional index and time for climbing up 10 steps in intent-to-treat 
patients (n = 100/group).
Variable Treatment 
Group
Week 0 Week 1 Week 2 Week 3 Week 4 % 
improvementa
VAS that assessed pain (mm)
Walking pain DJW 64.53 (24.92) 47.58* (25.33) 37.72* (25.00) 28.00* (23.25) 18.06* (20.76) 72.01
Diclofenac 64.78 (25.14) 44.08* (23.43) 34.99* (22.07) 24.21* (21.00) 14.31* (16.10) 77.91
Standing pain DJW 52.42 (25.87) 39.81* (26.09) 31.61* (24.89) 24.29* (22.98) 16.89* (20.59) 67.78
Diclofenac 53.52 (24.69) 37.60* (24.06) 28.19* (22.40) 21.12* (21.16) 12.86* (16.69) 75.97
Pain during climbing up and down stairs DJW 63.08 (20.87) 46.31* (26.56) 36.40* (25.67) 28.16* (24.03) 18.41* (21.50) 70.81
Diclofenac 62.69 (23.21) 43.90* (22.29) 32.61* (22.42) 24.59* (21.79) 15.83* (19.65) 74.75
Night pain DJW 50.15 (26.74) 33.44* (27.27) 23.56* (22.79) 15.68* (18.14) 9.27* (15.04) 81.52
Diclofenac 48.45 (28.18) 28.93* (22.82) 20.87* (19.56) 15.02* (17.87) 8.65* (14.68) 82.15
Resting pain DJW 38.48 (22.09) 27.25* (21.99) 19.96* (19.98) 12.64* (15.56) 7.42* (13.09) 80.72
Diclofenac 37.12 (26.08) 22.84* (20.62) 16.26* (18.19) 11.30* (16.40) 6.58* (13.96) 82.27




108.76* (92.54) 70.04* (83.94) 73.93
Diclofenac 266.55 (89.33) 177.34* (85.49) 132.91* (84.50) 96.21* (81.94) 58.23* (70.43) 78.15
Pain during the most painful knee movement DJW 82.25 (16.15) 63.31* (26.35) 49.77* (28.70) 37.69* (28.45) 26.81* (27.70) 67.40
Diclofenac 81.17 (16.56) 56.79* (24.87) 43.64* (27.30) 33.10* (27.17) 22.84* (25.85) 71.86
VAS that assessed stiffness (mm)
Morning stiffness DJW 53.53 (27.38) 36.61* (25.56) 28.04* (23.86) 19.66* (20.53) 12.34* (17.69) 76.95
Diclofenac 58.32 (26.40) 38.73* (23.87) 28.52* (21.93) 20.19* (20.23) 12.90* (17.34) 77.88
Stiffness after rest DJW 68.52 (22.76) 51.69* (24.93) 39.40* (25.31) 29.05* (24.60) 19.62* (23.06) 71.37
Diclofenac 70.45 (22.32) 49.71* (24.68) 39.54* (24.97) 28.23* (24.17) 18.90* (20.60) 73.17
Total stiffnessc DJW 122.05 (41.98) 88.30* (45.93) 67.44* (46.25) 48.71* (42.82) 31.96* (38.84) 73.81
Diclofenac 128.76 (42.34) 88.44* (43.84) 68.06* (43.03) 48.42* (41.97) 31.80* (36.07) 75.30
Lequesne's functional index (score) DJW 14.20 (3.13) 11.60* (4.11) 11.05* (4.04) 9.93* (4.40) 8.92* (4.60) 37.18
Diclofenac 14.80 (2.61) 10.89* (3.38) 10.65* (3.55) 9.59* (3.52) 8.64* (3.83) 41.62
Time for climbing up 10 steps (s) DJW 13.44 (4.85) 11.65* (4.75) 11.42* (4.67) 10.94* (4.73) 10.50* (4.38) 21.88
Diclofenac 13.32 (5.10) 11.26* (5.12) 11.14* (5.72) 10.61* (5.51) 10.18* (4.46) 23.57
Data represent mean (SD). aCalculated by (meanweek0-meanweek4) × 100/meanweek0. bSummation of VAS that assessed walking pain, standing pain, 
pain during climbing up and down stairs, night pain and resting pain. cSummation of VAS that assessed morning stiffness and stiffness after rest. *p < 
0.05 versus base-line value.BMC Complementary and Alternative Medicine 2004, 4:19 http://www.biomedcentral.com/1472-6882/4/19
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When the statistical analysis between groups was per-
formed, the mean changes in VAS that assessed pain dur-
ing climbing up and down the stairs, night pain, resting
pain, total pain, and time for climbing up 10 steps did not
differ significantly between both groups (Table 5). None-
theless, the mean changes in VAS that assessed walking
pain, standing pain, and stiffness were significantly differ-
ent during week 0–1, whereas, differences in mean
changes in Lequesne's functional index were found during
week 0–1 and 0–2. Afterwards, the mean changes in these
variables became no different throughout the study.
The physician's and patients' overall opinions on
improvement, as measured on VAS, are shown in Table 6.
The physician's overall opinion on improvement at each
time point did not significantly differ between the two
groups. However, differences between groups (DJW ver-
sus diclofenac group) were found in the patients' overall
opinion at week 1 (32.58 ± 23.18 versus 37.48 ± 18.59),
but no differences were demonstrated at the remaining
time-points.
The majority of patients in both groups experienced no
adverse events (72% vs. 73% for DJW and diclofenac
groups, respectively). All adverse events reported were
mild in intensity in both groups. The most common
adverse events occurring in the DJW and diclofenac group
were raised blood pressure (16% vs. 19%), central nerv-
ous system symptoms including dizziness, somnolence
and drowsiness (16% vs. 11%), and gastrointestinal
symptoms including nausea/vomiting, dyspepsia,
diarrhea and constipation (12% vs. 5%). The least com-
mon adverse events were increased appetite, cramp, rash
and flu. More than one adverse events might be occurred
in some patients. However, the percentages of patients
who experienced each adverse event in both groups were
not significantly different.
In summary, the VAS that assessed pain and stiffness,
Lequesne's functional index and time for climbing up 10
steps at each time point decreased significantly in the DJW
and diclofenac group when compared to their own base-
line values. The mean changes in all VAS that assessed
Table 5: Mean changes of VAS that assessed pain and stiffness, Lequesne's functional index and time for climbing up 10 steps in intent-
to-treat patients (n = 100/group).
Variable Treatment 
Group
Week 0–1 Week 0–2 Week 0–3 Week 0–4
VAS that assessed pain (mm)
Walking pain DJW -16.96 (1.68) -26.82 (1.97) -36.54 (2.31) -46.48 (2.41)
Diclofenac -20.70† (1.60) -29.80 (1.95) -40.58 (2.26) -50.47 (2.38)
Standing pain DJW -12.61 (1.80) -20.81 (2.23) -28.13 (2.28) -35.53 (2.34)
Diclofenac -15.93† (1.33) -25.33 (1.83) -32.41 (2.04) -40.66 (2.25)
Pain during climbing up and down stairs DJW -16.78 (1.95) -26.68 (2.30) -34.93 (2.26) -44.67 (2.22)
Diclofenac -18.79 (1.40) -30.08 (1.91) -38.11 (2.04) -46.86 (2.35)
Night pain DJW -16.71 (2.32) -26.60 (2.25) -34.47 (2.42) -40.88 (2.59)
Diclofenac -19.52 (1.98) -27.58 (2.30) -33.43 (2.51) -39.80 (2.81)
Resting pain DJW -11.23 (1.24) -18.52 (1.46) -25.84 (1.86) -31.06 (2.02)
Diclofenac -14.28 (1.34) -20.86 (1.91) -25.82 (2.07) -30.54 (2.38)
Total paina DJW -74.27 (6.53) -119.42 (7.42) -159.90 (7.85) -198.61 (8.51)
Diclofenac -89.21 (5.25) -133.64 (7.02) -170.34 (7.65) -208.33 (9.03)
Pain during the most painful knee movement DJW -18.94 (2.11) -32.48 (2.63) -44.56 (2.77) -55.44 (2.67)
Diclofenac -24.38 (2.10) -37.53 (2.51) -48.07 (2.57) -58.33 (2.59)
VAS that assessed stiffness (mm)
Morning stiffness DJW -16.93 (1.98) -25.50 (2.24) -33.87 (2.46) -41.19 (2.58)
Diclofenac -19.59† (1.69) -29.80 (2.10) -38.13 (2.47) -45.42 (2.63)
Stiffness after rest DJW -16.83 (1.97) -29.12 (2.41) -39.48 (2.50) -48.91 (2.54)
Diclofenac -20.74† (1.72) -30.91 (2.07) -42.22 (2.29) -51.55 (2.40)
Total stiffnessb DJW -33.76 (3.48) -54.62 (4.02) -73.35 (4.21) -90.10 (4.27)
Diclofenac -40.33† (3.05) -60.71 (3.72) -80.35 (4.21) -96.97 (4.47)
Lequesne's functional index (score) DJW -2.60 (0.34) -3.15 (0.32) -4.28 (0.37) -5.29 (0.38)
Diclofenac -3.92† (0.31) -4.16† (0.32) -5.22 (0.36) -6.16 (0.40)
Time for climbing up 10 steps (s) DJW -1.79 (0.33) -2.02 (0.31) -2.50 (0.32) -2.94 (0.32)
Diclofenac -2.05 (0.31) -2.18 (0.34) -2.71 (0.34) -3.13 (0.33)
Data represent mean (SD). aSummation of VAS that assessed walking pain, standing pain, pain during climbing up and down stairs, night pain and 
resting pain. bSummation of VAS that assessed morning stiffness and stiffness after rest. †p < 0.05 versus the DJW group at the same duration of 
treatment.BMC Complementary and Alternative Medicine 2004, 4:19 http://www.biomedcentral.com/1472-6882/4/19
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pain, except those for walking and standing, did not differ
significantly between both groups. The differences in
mean changes in the VAS that assessed walking pain,
standing pain and stiffness were found only during week
0–1, whereas, those in Lequesne's functional index were
found during week 0–1 and 0–2.
Discussion
Since the preparations and dosages of DJW and diclofenac
were different, this study was designed as a randomized,
double dummy, controlled trial in order to completely
blind both patients and physician (double-blind). There-
fore, the placebo of DJW was also prescribed for the
patients in the diclofenac group, and vice versa, the pla-
cebo of diclofenac was prescribed for the patients in the
DJW group.
Among the 15 herbs used as raw materials in DJW, Xixin
(Herba Asari) seemed to be the most toxic, due to its pun-
gent taste and warm property [16]. Generally, a large dose
of this herb is not recommended in a tropical country
(such as Thailand) because of the potential aggravation of
internal heat. Thus, the amount of Xixin in the DJW recipe
used in this study was reduced from 7.75% to 2.5%.
In an ITT analysis (and analysis on completers), the mean
changes in some variables between the two groups were
significantly different after the first few weeks of treat-
ment, and became no different afterwards. These differ-
ences suggest that the onset of DJW is significantly slower
than diclofenac for at least 2 weeks (with respect to walk-
ing pain, standing pain, morning stiffness, stiffness after
rest, total stiffness and patients' overall opinion) or 3
weeks (with respect to Lequesne's functional index). The
reason why DJW needs a few weeks to exert its effect may
be due to 3 possibilities. Firstly, from the pharmacokinetic
point of view, the elimination half-life of the active ingre-
dients in DJW might be too long, and therefore needs
weeks to accumulate until a steady state concentration is
reached (normally 4–5 half-lives) and its maximal thera-
peutic effect is evident. Secondly, from the pharmacody-
namic point of view, DJW may exert its effects via several
probable mechanisms (similar to many novel biologic
treatments of arthropathy) involved modifications of car-
tilage metabolism, normalized viscosity and elasticity of
synovial fluid, etc. These mechanisms of action might
resemble many symptomatic slow acting drugs in osteoar-
thritis (SYSADOA) such as glucosamine sulfate, intra-
artricular hyaluronan, and others. These interventions
always need a period of time to exert their therapeutic
action. Thirdly, the major effect of DJW might be the
result from placebo effect and/or natural fluctuation of
the OA symptoms. It could be simply that diclofenac
worked quickly, but patients in both groups got better
anyway by 2–3 weeks. Although the last possibility cannot
be entirely ruled out, but it seems unlikely because even
there is a tendency of OA symptoms to improve after pla-
cebo treatment, it has been reported that diclofenac was
significantly superior to placebo in relieving pain,
improving stiffness, and improving physical function
after 4 weeks of treatment [17]. Furthermore, we also
found that oral administration of the ethanol extract of
DJW possessed both central and peripheral analgesic
activities in animal model, even when the DJW extract was
given in the equivalent dose used in human (mg/kg of
human dose corrected by intra- and inter-specie varia-
tions) [to be published data]. In clinical practice, this
slower onset of action and probable need for rescue anal-
gesics (e.g., paracetamol as needed) during the first 2–3
weeks after initiation of DJW should be the important
limitations of using DJW as an alternative treatment for
OA of the knee. Moreover, the patient's compliance with
such a high dosage of DJW (9 g/day or 18 capsules/day) is
an important issue to be concerned.
Since this study demonstrated that approximately 30% of
study subjects in each group experienced adverse events,
this data suggest that the toxicity profiles of DJW are sim-
ilar to diclofenac. Therefore, cautious use of DJW should
be considered in the same manner as using diclofenac
including other NSAIDs. However, the gastrointestinal
adverse effects in the diclofenac group were quite low
when compared to other short-term NSAIDs studies
[18,19]. This might be due to the exclusion of patients
with a high risk of adverse effects from NSAIDs during the
screening visit. Since the relief of joint pain afforded by
Table 6: VAS that assessed physician's and patients' overall opinions on improvementa during treatment (intent-to-treat data set).
Variable Treatment group n Week 1 Week 2 Week 3 Week 4
Physician's overall opinion DJW 98b 56.69 (11.32) 57.30 (11.32) 60.06 (12.47) 62.55 (11.67)
Diclofenac 97b 59.84 (7.53) 59.63 (7.74) 62.11 (7.57) 63.35 (7.90)
Patients' overall opinion DJW 98b 32.58 (23.18) 45.53 (24.74) 58.10 (26.84) 71.13 (24.68)
Diclofenac 97b 37.48* (18.59) 50.24 (18.79) 62.88 (19.75) 75.30 (17.95)
Data represent mean (SD). a0 = no improvement, 100 = best possible improvement. b2 patients in the DJW group and 3 patients in the diclofenac 
group could not be assessed due to loss to follow up or withdrawal during week 0. *p < 0.05 versus the DJW group at the corresponding week.Publish with BioMed Central    and   every 
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paracetamol is comparable with that achievable with
NSAIDs, paracetamol merits a trial as initial therapy,
based on its overall cost, efficacy, and toxicity profile
[3,7]. In this circumstance, the rather high rate of adverse
events from DJW should be another limitation of using
DJW as an alternative, especially to paracetamol, in symp-
tomatic treatment of OA of the knee.
Conclusion
DJW demonstrates clinically comparable efficacy to
diclofenac after 4 weeks of treatment. However, the slow
onset of action as well as approximately equal rate of
adverse events to diclofenac might limit its alternative role
in treatment of OA of the knee.
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